Etrasimod tablets (Etrasimod)-Velsipity market reference price and detailed analysis of drug purchase channels

Etrasimod -Velsipity is a new S1P (sphingosine -1-phosphate) receptor modulator for the treatment of moderate to severe ulcerative colitis (UC). Arena Pharmaceuticals was developed and later launched globally by Pfizer (Pfizer). The drug was approved by the FDA in October 2023, becoming another oral small molecule immunomodulator used in the field of inflammatory bowel disease after Ozanimod. Due to its higher target selectivity (focused effects S1P1, S1P5), it improves inflammation while having relatively mild side effects, especially in terms of heart rate effects, liver function fluctuations and infection risks. It has better safety. Currently, this drug is not available on the mainland of China and is not included in medical insurance. Domestic patients usually need to obtain it through overseas channels if they need to use it.

From the market price point of view, Etrasimod tablets (Etrasimod) are relatively new original research and innovative drugs, and the international price is relatively high. According to the latest overseas market information, the European version of the drug is sold for approximately 1～3 RMB per box. The specific price will vary depending on national taxes and fees, pharmacy channels, logistics costs and exchange rate fluctuations. The price of the American version is similar to that of the European version, but the price difference is usually larger after private insurance reimbursement. Due to the short time the drug has been on the market, there are currently no generic versions of the drug in the world. If low-priced "imitations" appear on the market, you need to be highly vigilant about the risk of counterfeit drugs. Therefore, patients should pay special attention to the formality of the channels when purchasing to avoid products from unknown sources that may affect the treatment effect or even cause safety issues.

Regarding drug purchasing channels, since it has not yet been launched in China, patients generally obtain it through international medical institutions, cross-border medical service platforms, formal overseas pharmacies or hospital cooperation channels. Some medical institutions that provide cross-border drug purchasing services can assist patients with full-process services such as English prescriptions, order placement, and customs clearance to improve the efficiency and safety of drug purchasing. In addition, some patients will also choose to go abroad for medical treatment or take prescriptions out of the clinic and bring them back home. However, it should be noted that different countries have different requirements for carrying quantities and declarations of prescription drugs. Be sure to consult customs and hospitals in advance to avoid unnecessary risks.

Overall, Etrasimod (Etrasimod) is a FDA newly approved highly selective S1PModulators have good efficacy, safety and convenient oral administration, so they have attracted attention among UC patient groups. However, since it has not yet been launched in China, the purchase cost is high and it relies on overseas channels. Patients should use it under the evaluation of professional doctors and strictly ensure that the drug purchase channels are formal and reliable. With the approval of more countries in the future and the possible advancement of medical insurance negotiations, the accessibility of the drug in the country is expected to further increase.

References:https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-velsipity